Lenvatinib (E7080) CAS NO.417716-92-8

Lenvatinib Usage And Synthesis
Thyroid cancer drugs    Lenvatinib is a thyroid cancer drug developed by Eisai Corporation of Japan (Code: E7080), belonging to the inhibitor of oral multi-receptor tyrosine kinase (RTK) and can inhibit the kinase activity of the vascular endothelial growth factor (VEGF) Receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib can also inhibit the involvement of other RTKs in pathological angiogenesis, tumor growth, and cancer progression except for their normal cellular functions including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-derived growth factor receptor (PDGFR [alpha]), KIT, and RET.
[Indications]: Lenvatinib is suitable for the treatment of patients of thyroid cancer of local recurrence or metastasis type, progressivity type and radioactive iodine-refractory differentiated type.
 

Lenvatinib Basic information
Thyroid cancer drugs Biological activity In vitro study In vivo studies Feature
Product Name:    Lenvatinib
Synonyms:    4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide;E7080;LENVATINIB;E7080 (Lenvatinib);Lenvatinib (E7080);ER-203492-00;1-(4-(6-carbamoyl-7-methoxyquinolin-4-yloxy)-2-chlorophenyl)-3-cyclopropylurea;4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide XEN445
CAS:    417716-92-8
MF:    C21H19ClN4O4
MW:    426.85
EINECS:    1592732-453-0
Mol File:    417716-92-8.mol

Lenvatinib Chemical Properties
Boiling point     627.2±55.0 °C(Predicted)
density     1.46
pka    13.09±0.70(Predicted)
CAS DataBase Reference    417716-92-8